Hemab Therapeutics Holdings Common Stock Current Assets

Hemab Therapeutics Holdings Common Stock's current assets stands at $460M as of June 2026. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether Hemab Therapeutics Holdings Common Stock's current assets is expanding or contracting. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Hemab Therapeutics Holdings Common Stock's current assets evolved across reporting periods, while the comparison chart places COAG next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. Hemab Therapeutics Holdings Common Stock's reading of $460M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.